Porter J B, Hoyes K P, Abeysinghe R D, Brooks P N, Huehns E R, Hider R C
Department of Clinical Haematology, University College and Middlesex School of Medicine, London, UK.
Blood. 1991 Nov 15;78(10):2727-34.
Five orally effective iron chelators of the 3-hydroxypyridin-4-one series have been administered intraperitoneally to iron-overloaded and nonoverloaded male mice at a dose of 200 mg/kg/24 h for a total of 60 days to investigate the effect on iron loading and toxicity. There was a significant reduction in hepatic iron at the end of the study in the iron-overloaded mice with all compounds studied using chemical iron quantitation (P less than .001) and with Perls' stain (P less than .01). Liver iron removal with the hydroxypyridinones ranged from 37% with CP20 to 63% with CP51, compared with 46% removal for desferrioxamine (DFO). There was no significant reduction in splenic or cardiac iron with any chelator. There were no deaths in iron-overloaded animals receiving any of the hydroxypyridin-4-ones, but significantly more deaths in the nonoverloaded groups as a whole (P less than .03). No weight loss was observed with any chelator. Significant reductions in hemoglobin and white cell count were observed with CP20(L1). No histologic abnormalities of kidney, spleen, bone marrow, or stifle joints were observed. Intracytoplasmic inclusion bodies were observed in the centrilobular hepatocytes of animals administered each of the hydroxypyridin-4-ones, while the DFO-treated and control groups showed no such changes.
已将5种3-羟基吡啶-4-酮系列的口服有效铁螯合剂以200mg/kg/24小时的剂量腹腔注射给铁过载和未过载的雄性小鼠,共60天,以研究其对铁负荷和毒性的影响。在研究结束时,使用化学铁定量法(P小于0.001)和Perls染色法(P小于0.01)对所有研究的化合物进行检测,铁过载小鼠的肝脏铁含量均显著降低。羟基吡啶酮类药物的肝脏铁清除率在CP20为37%至CP51为63%之间,而去铁胺(DFO)的清除率为46%。任何螯合剂均未使脾脏或心脏铁含量显著降低。接受任何一种羟基吡啶-4-酮的铁过载动物均无死亡,但整个未过载组的死亡数显著更多(P小于0.03)。未观察到任何螯合剂导致体重减轻。CP20(L1)可使血红蛋白和白细胞计数显著降低。未观察到肾脏、脾脏、骨髓或膝关节的组织学异常。在给予每种羟基吡啶-4-酮的动物的小叶中央肝细胞中观察到胞质内包涵体,而去铁胺治疗组和对照组未出现此类变化。